Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2020 3
2021 7
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Immune checkpoint inhibitors in penile cancer.
Buonerba C, Scafuri L, Costabile F, D'Ambrosio B, Gatani S, Verolino P, Trolio RD, Cosimato V, Verde A, Lorenzo GD. Buonerba C, et al. Among authors: verde a. Future Sci OA. 2021 May 21;7(7):FSO714. doi: 10.2144/fsoa-2021-0044. eCollection 2021 Aug. Future Sci OA. 2021. PMID: 34258024 Free PMC article. No abstract available.
Instant messaging in cancer care.
Buonerba C, Calabrese AN, Imperioso G, Piscosquito A, Verde A, Vaia A, Scafuri L, Crocetto F, Leopardo D, Rocco B, Del Giudice F, Tufano A, Casale B, Cappuccio F, Chiancone F, Di Trolio R, Di Lorenzo G. Buonerba C, et al. Among authors: verde a. Oncology. 2024 Jan 23. doi: 10.1159/000536345. Online ahead of print. Oncology. 2024. PMID: 38262385
COVID-19 and prostate cancer: a complex scenario with multiple facets.
Crocetto F, Buonerba L, Scafuri L, Caputo V, Barone B, Sciarra A, Verde A, Calogero A, Buonerba C, Lorenzo GD. Crocetto F, et al. Among authors: verde a. Future Sci OA. 2021 Oct;8(1):FSO. doi: 10.2144/fsoa-2021-0113. Epub 2021 Nov 23. Future Sci OA. 2021. PMID: 34898669 Free PMC article. No abstract available.
Urologic malignancies: advances in the analysis and interpretation of clinical findings.
Crocetto F, Buonerba C, Caputo V, Ferro M, Persico F, Trama F, Iliano E, Rapisarda S, Bada M, Facchini G, Verde A, Placido S, Barone B. Crocetto F, et al. Among authors: verde a. Future Sci OA. 2021 Feb 4;7(4):FSO674. doi: 10.2144/fsoa-2020-0210. Future Sci OA. 2021. PMID: 33815820 Free PMC article. No abstract available.
Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone.
Crocetto F, Ferro M, Buonerba C, Bardi L, Dolce P, Scafuri L, Mirto BF, Verde A, Sciarra A, Barone B, Calogero A, Sagnelli C, Busetto GM, Del Giudice F, Cilio S, Sonpavde G, Di Trolio R, Della Ratta GL, Barbato G, Di Lorenzo G. Crocetto F, et al. Among authors: verde a. Crit Rev Oncol Hematol. 2023 Aug;188:104059. doi: 10.1016/j.critrevonc.2023.104059. Epub 2023 Jun 21. Crit Rev Oncol Hematol. 2023. PMID: 37353178 Review.
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Ferro M, Crocetto F, Tataru S, Barone B, Dolce P, Lucarelli G, Sonpavde G, Musi G, Antonelli A, Veccia A, Terracciano D, Busetto GM, Del Giudice F, Marchioni M, Schips L, Porpiglia F, Fiori C, Carrieri G, Lasorsa F, Verde A, Scafuri L, Buonerba C, Di Lorenzo G. Ferro M, et al. Among authors: verde a. Clin Genitourin Cancer. 2023 Oct;21(5):574-583. doi: 10.1016/j.clgc.2023.05.017. Epub 2023 May 27. Clin Genitourin Cancer. 2023. PMID: 37419854
Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond.
Buonerba C, Ingenito C, Di Trolio R, Cappuccio F, Rubino R, Piscosquito A, Verde A, Costabile F, Iuliucci M, Crocetto F, Chiancone F, Nacchia A, Campitelli A, Scafuri L, Sanseverino R, Di Lorenzo G. Buonerba C, et al. Among authors: verde a. Oncol Ther. 2024 Feb 28. doi: 10.1007/s40487-024-00266-7. Online ahead of print. Oncol Ther. 2024. PMID: 38416326 Free article.
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, Pagliuca M, Morra R, Riccio V, Ribera D, De Placido P, Romeo V, Crocetto F, Longo N, Imbimbo C, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: verde a. Cancers (Basel). 2020 Feb 10;12(2):408. doi: 10.3390/cancers12020408. Cancers (Basel). 2020. PMID: 32050629 Free PMC article. Review.
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.
Ferro M, Lucarelli G, Crocetto F, Dolce P, Verde A, La Civita E, Zappavigna S, de Cobelli O, Di Lorenzo G, Facchini BA, Scafuri L, Onofrio L, Porreca A, Busetto GM, Sonpavde G, Caraglia M, Klain M, Terracciano D, De Placido S, Buonerba C. Ferro M, et al. Among authors: verde a. Crit Rev Oncol Hematol. 2021 Jan;157:103198. doi: 10.1016/j.critrevonc.2020.103198. Epub 2020 Dec 13. Crit Rev Oncol Hematol. 2021. PMID: 33316417
18 results